Cover note Coramine and other analeptics
The twentieth century saw the development of a new range of anaesthetic drugs. These were intended to provide greater patient comfort but proved less predictable than the familiar, rapidly eliminated gases and vapours. As a result, reports of prolonged unconsciousness and respiratory depression appeared in the literature from the 1920s onwards.
One of the first of these new medications was Avertin, tribromethyl alcohol. Administered rectally, often on the ward, it produced hours of unconsciousness with the patient frequently completely unaware that surgery had taken place. It was essentially premedication, known as "basal narcosis", usually supplemented by ether anaesthesia during the procedure itself. While this could be beneficial, particularly in patients with thyrotoxicosis, there were complications, notably respiratory depression. Due to the prolonged nature of the anaesthesia, this often happened long after the operation, in some quiet corner of the ward, away from the watchful eye of the anaesthetist. Attempts were made to wash out the rectum at the end of the procedure, but by then the solution had all been absorbed. The next obvious step was to address the question of "antidotes and detoxication" 1 . Thyroxine administration was suggested in the hope that increasing the metabolic rate would hasten recovery. This fairly convoluted approach to the problem proved extremely unreliable since, although it was shown to shorten the anaesthesia time, it was necessary to give it for several days before the operation in order for it to be effective. This process was sometimes "attended by undesirable symptoms" 1 . The pre-emptive nature of this solution also made it impractical in emergencies.
By this time, adrenaline had established its place as the most appropriate treatment for cardiovascular collapse, but less specific drugs, such as camphor and strychnine, continued to be used for their added respiratory stimulatory properties. Since camphor is not water-soluble, an increasing need for intravenous drugs to treat respiratory depression saw a search for water-soluble preparations of camphor 2 . These experiments were only partially successful, but led researchers to investigate a variety of pyridines, such as nicotine 3 . The most powerful of the pyridines was pyridine β-carboxylic acid diethylamide, or Coramine®.
Coramine was first manufactured by the Gessellschaft für Chemische Industrie in Basel, Switzerland. Later, when the patent rights expired, other companies produced it under trade names such as Nicamide® and Anacardone® 2 . It was marketed as an analeptic, a central nervous system stimulant. Experimental studies showed that the therapeutic effects of this drug were principally due to stimulation of centres in the medulla. In large doses it was also a spinal cord stimulant, leading to muscular twitching and convulsive movement. Reportedly it had a wide margin of safety but fatal doses caused respiratory failure due to spasm of the respiratory muscles. Coramine also had beneficial effects on the heart, with dilation of the coronary arteries and inconsistent increases in cardiac output.
As experience with rectal Avertin grew, various methods were used to overcome the respiratory depression, a phenomenon often compounded by concomitant administration of preoperative morphine. The most common solution was to administer ether anaesthesia with 5% carbon dioxide and oxygen which "rapidly restored normal colour" 4 . Killian was the first to suggest that large doses of Coramine could be used to reverse the Avertin narcosis, and therefore the respiratory depression 5 . Subsequently Kennedy and colleagues began administering Coramine for Avertin-related respiratory depression, "using smaller doses [than Killian], since complete interruption of the anaesthetic was not desired..." 1 . They used 2-3 ml intramuscularly with a rapid improvement in colour and deepening of respiration. As a bonus they noted "slack jaw muscles stiffened, and the jaw no longer had to be supported" 1 . Also beneficial was a rise in blood pressure, and slowing and strengthening of the pulse. Importantly they noted that the depth of anaesthesia was not adversely affected, although the patients appeared to awaken more quickly at the conclusion of the operation.
Avertin gradually fell out of favour as the ensuing decades saw a rapid increase in the use of barbiturates in both anaesthesia and general medicine. These too led to respiratory depression, a problem which extended beyond the 
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operating room with the widespread use of barbiturates in the community. Overdoses were common and Coramine was just one of many drugs used for the treatment of barbiturate coma. Its beneficial effects were demonstrated in a study in a Boston psychiatric clinic where a number of mentally ill patients "with no physical illness" were given large doses of barbiturates 6 . Once the patients were unconscious, attempts were made to rouse them by shaking. If this was unsuccessful "pinpricking was resorted to". If this also failed, intravenous Coramine was administered every ten minutes until the patient was awake. A control group "remained unconscious for hours" while most of the 84 patients given Coramine were awake in minutes. Of the latter group, many had prolonged hiccoughs and some projectile vomiting but "no alteration in emotional or intellectual state". In anaesthesia, increasing use of barbiturates saw greater use of analeptics to "accelerate the return of reflexes, consciousness and physical activity …" 7 . There were many comparative studies, testing the efficacy of Coramine against other popular analeptics. A 1948 study showed the plant extract, picrotoxin, to be more effective than amphetamine sulphate (benzedrine); both were shown to be more effective than Coramine 8 . This study suggested that the use of analeptics would help "ensure an uneventful post-operative recovery". Like many other studies of the 1940s and 1950s, it particularly recommended analeptics for outpatient surgery, and major abdominal and chest operations.
During the 1960s, a number of new analeptics appeared on the market, notably methylphenidate (Ritalin®) and bemegride. While these were found to be similarly efficacious to Coramine and picrotoxin in reversing light hypnosis, both were superior in the treatment of severe barbiturate coma 9 . These drugs soon replaced the older analeptics for this purpose. At the same time, the use of analeptics in anaesthesia was being questioned: "Anesthesiologists have little need for respiratory stimulants. Most of us rely on the old dictum that prevention is better than cure and recognize that analeptics are convulsants which neither displace the offending agent from its receptors nor hasten its elimination" 10 .
However, the synthesis of doxapram in 1962 prolonged the debate on analeptics in anaesthesia. Doxapram substantially increased respiratory rate and depth with little effect on arousal, giving it a much higher safety margin than the other analeptics 8 . Winnie and Collins considered it to be "a pure pharmacologic ventilator" and suggested there were indications for its use "where the transient increased cost of breathing is of no concern and the effects of the induced hyperventilation may be of considerable benefit to the patient" 11 . Doxapram subsequently found a fairly niche market in intensive care and respiratory medicine. It still has some protagonists and potential uses are still being postulated 12 . Similarly Solt and colleagues recently suggested a role for methylphenidate in the reversal of "general anaesthesia-induced unconsciousness" in light of improved understanding of the neural pathways involved in anaesthesia 13 . It would seem that the debate about the role of analeptics in anaesthesia is not over.
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